Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 9051-97-2
2. 9012-72-0
3. (2s,3r,4s,5r,6r)-2-[(2r,3r,4r,5s)-3,5-dihydroxy-2-(hydroxymethyl)oxan-4-yl]oxy-4-[(2s,3r,5s,6r)-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-3,5-diol
4. .beta.-d-glucan, (1?3)-
5. Yg30829
6. B-d-glucan-from Yeast (saccharomyces Cerevisiae)
Molecular Weight | 472.4 g/mol |
---|---|
Molecular Formula | C18H32O14 |
XLogP3 | -4.3 |
Hydrogen Bond Donor Count | 9 |
Hydrogen Bond Acceptor Count | 14 |
Rotatable Bond Count | 7 |
Exact Mass | 472.17920569 g/mol |
Monoisotopic Mass | 472.17920569 g/mol |
Topological Polar Surface Area | 228 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 582 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 13 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
The effect of oat beta glucan on the study primary endpoint is change in LDL-C, and some positive findings observed with different parameters, there were dosage-related responses in weight and body-mass index at 12 weeks but they also did not reach statistical significance.
Lead Product(s): Beta Glucan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 17, 2021
Lead Product(s) : Beta Glucan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The effect of oat beta glucan on the study primary endpoint is change in LDL-C, and some positive findings observed with different parameters, there were dosage-related responses in weight and body-mass index at 12 weeks but they also did not reach stat...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2021
Details:
The agreement grants Define Biotech the exclusive right to distribute maitake mushroom, rich in bioactive polysaccharides, especially beta-glucans, as new dietary supplement in China and Taiwan in exchange for the commitment of the new product over the three-year period.
Lead Product(s): Beta Glucan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Other Small Molecule
Sponsor: ABVC BioPharma
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Agreement September 12, 2021
Lead Product(s) : Beta Glucan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : ABVC BioPharma
Deal Size : $3.0 million
Deal Type : Agreement
Details : The agreement grants Define Biotech the exclusive right to distribute maitake mushroom, rich in bioactive polysaccharides, especially beta-glucans, as new dietary supplement in China and Taiwan in exchange for the commitment of the new product over the t...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 12, 2021
Details:
Under the collaboration, pre-clinical studies using methods developed by the Angiogenesis Foundation will be conducted to characterize the in vivo bioactivity of Ceapro’s oat-derived bioactive products, beta glucan and avenanthramides.
Lead Product(s): Beta Glucan
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: Angiogenesis Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 23, 2021
Lead Product(s) : Beta Glucan
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Angiogenesis Foundation
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, pre-clinical studies using methods developed by the Angiogenesis Foundation will be conducted to characterize the in vivo bioactivity of Ceapro’s oat-derived bioactive products, beta glucan and avenanthramides.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 23, 2021
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
16
PharmaCompass offers a list of Beta Glucan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Beta Glucan manufacturer or Beta Glucan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Beta Glucan manufacturer or Beta Glucan supplier.
PharmaCompass also assists you with knowing the Beta Glucan API Price utilized in the formulation of products. Beta Glucan API Price is not always fixed or binding as the Beta Glucan Price is obtained through a variety of data sources. The Beta Glucan Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Beta Glucan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Beta Glucan, including repackagers and relabelers. The FDA regulates Beta Glucan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Beta Glucan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Beta Glucan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Beta Glucan supplier is an individual or a company that provides Beta Glucan active pharmaceutical ingredient (API) or Beta Glucan finished formulations upon request. The Beta Glucan suppliers may include Beta Glucan API manufacturers, exporters, distributors and traders.
click here to find a list of Beta Glucan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Beta Glucan DMF (Drug Master File) is a document detailing the whole manufacturing process of Beta Glucan active pharmaceutical ingredient (API) in detail. Different forms of Beta Glucan DMFs exist exist since differing nations have different regulations, such as Beta Glucan USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Beta Glucan DMF submitted to regulatory agencies in the US is known as a USDMF. Beta Glucan USDMF includes data on Beta Glucan's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Beta Glucan USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Beta Glucan suppliers with USDMF on PharmaCompass.
Beta Glucan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Beta Glucan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Beta Glucan GMP manufacturer or Beta Glucan GMP API supplier for your needs.
A Beta Glucan CoA (Certificate of Analysis) is a formal document that attests to Beta Glucan's compliance with Beta Glucan specifications and serves as a tool for batch-level quality control.
Beta Glucan CoA mostly includes findings from lab analyses of a specific batch. For each Beta Glucan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Beta Glucan may be tested according to a variety of international standards, such as European Pharmacopoeia (Beta Glucan EP), Beta Glucan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Beta Glucan USP).